Valuation
- Market cap
- 6,626,000
- Revenue TTM
- $1,710,000
- Net income TTM
- $-4,300,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -251.46%
- Debt to equity
- 0.06
Trading
- Volume
- 378,291
- Avg volume
- 1,507,805
- Day's range
- $2.30 – $2.66
- Shares out
- 2,588,000
- Stochastic %K
- 44%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving m...
Show more
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 866 445 4886
- Website
- https://pmgcholdings.com
- Address
- 120 Newport Center Drive, Suite 249, Newport Beach, United States
Latest news
No headlines yet.